

# Geert Leroux-Roels

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/463429/publications.pdf>

Version: 2024-02-01

108  
papers

4,212  
citations

117625

34  
h-index

138484

58  
g-index

112  
all docs

112  
docs citations

112  
times ranked

7215  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. <i>Cell</i> , 2016, 167, 643-656.e17.	28.9	373
2	Unmet needs in modern vaccinology. <i>Vaccine</i> , 2010, 28, C25-C36.	3.8	257
3	Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness. <i>Journal of Infectious Diseases</i> , 2014, 209, 1873-1881.	4.0	206
4	AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 485-496.	9.1	143
5	Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent <i>Plasmodium falciparum</i> infection. <i>Journal of Clinical Investigation</i> , 2014, 124, 140-144.	8.2	140
6	Improved CD4+ T cell responses to <i>Mycobacterium tuberculosis</i> in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial. <i>Vaccine</i> , 2013, 31, 2196-2206.	3.8	135
7	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. <i>Gut</i> , 2017, 66, 920-929.	12.1	113
8	Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. <i>Vaccine</i> , 2021, 39, 1310-1318.	3.8	113
9	Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. <i>Frontiers in Immunology</i> , 2017, 8, 943.	4.8	111
10	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27.	3.2	90
11	Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2014, 13, 136.	2.3	79
12	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 931-941.	1.9	79
13	A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. <i>Vaccine</i> , 2004, 22, 3080-3086.	3.8	74
14	Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. <i>PLoS ONE</i> , 2013, 8, e55438.	2.5	69
15	A genetically attenuated malaria vaccine candidate based on <i>P. falciparum</i> b9/slarp gene-deficient sporozoites. <i>ELife</i> , 2014, 3, .	6.0	68
16	Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1057-1071.	3.1	64
17	Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1. <i>Journal of Biological Chemistry</i> , 2015, 290, 4022-4037.	3.4	63
18	A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B <i>Streptococcus</i> vaccine for use in non-pregnant and pregnant women. <i>Vaccine</i> , 2016, 34, 1786-1791.	3.8	60

#	ARTICLE	IF	CITATIONS
19	Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses. <i>Journal of Virology</i> , 2014, 88, 5502-5510.	3.4	59
20	Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 597-607.	4.0	59
21	Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. <i>Vaccine</i> , 2014, 32, 6838-6846.	3.8	56
22	Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2211-2219.	3.3	54
23	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with <i>in vitro</i> resistance to SR-BI-targeting agents. <i>Hepatology</i> , 2014, 60, 1508-1518.	7.3	50
24	Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials. <i>Vaccine</i> , 2015, 33, 577-584.	3.8	50
25	Influenza virus-specific antibody dependent cellular cytotoxicity induced by vaccination or natural infection. <i>Vaccine</i> , 2017, 35, 238-247.	3.8	49
26	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. <i>Lancet</i> , The, 2021, 397, 39-50.	13.7	49
27	Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. <i>Antiviral Research</i> , 2017, 141, 150-154.	4.1	46
28	Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. <i>Journal of General Virology</i> , 2002, 83, 1281-1289.	2.9	42
29	Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. <i>Vaccine</i> , 2015, 33, 1084-1091.	3.8	42
30	Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 321-330.	9.1	42
31	<i>In vivo</i> and <i>in vitro</i> metabolism of the synthetic cannabinoid JWH-200. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 2115-2126.	1.5	41
32	LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles. <i>Journal of General Virology</i> , 2002, 83, 2279-2289.	2.9	39
33	Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv067.	0.9	39
34	Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1271-1281.	9.1	39
35	Persistence of antibodies 20 years after vaccination with a combined hepatitis A and B vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 972-980.	3.3	38
36	The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. <i>Journal of General Virology</i> , 2005, 86, 75-84.	2.9	34

#	ARTICLE	IF	CITATIONS
37	Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. <i>Vaccine</i> , 2013, 31, 3739-3746.	3.8	34
38	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. <i>Npj Vaccines</i> , 2021, 6, 78.	6.0	34
39	Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0157385.	2.5	33
40	Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in <i>Bacillus Calmette-Guérin</i> -Vaccinated Adults. <i>Frontiers in Immunology</i> , 2018, 9, 564.	4.8	33
41	A <i>Plasmodium berghei</i> sporozoite-based vaccination platform against human malaria. <i>Npj Vaccines</i> , 2018, 3, 33.	6.0	32
42	A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59A <sup>®</sup> -adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1701-1710.	3.3	31
43	Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1066-1075.	2.0	31
44	Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. <i>Hepatology</i> , 2016, 63, 1120-1134.	7.3	30
45	Safety and immunogenicity of non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine. <i>Vaccine</i> , 2019, 37, 3113-3122.	3.8	30
46	Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. <i>Vaccine</i> , 2019, 37, 2694-2703.	3.8	30
47	Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable <i>Haemophilus influenzae</i> (NTHi) protein vaccine in adults. <i>Vaccine</i> , 2016, 34, 3156-3163.	3.8	27
48	Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children. <i>PLoS ONE</i> , 2014, 9, e115126.	2.5	26
49	In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). <i>Forensic Toxicology</i> , 2013, 31, 212-222.	2.4	25
50	Anti-CD81 but not anti-SR-BI blocks <i>Plasmodium falciparum</i> liver infection in a humanized mouse model. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1784-7.	3.0	25
51	Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferiority trial. <i>Vaccine</i> , 2017, 35, 6321-6328.	3.8	25
52	Influenza symptoms and their impact on elderly adults: randomised trial of AS03 <sup>®</sup> -adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 452-462.	3.4	24
53	Old and new adjuvants for hepatitis B vaccines. <i>Medical Microbiology and Immunology</i> , 2015, 204, 69-78.	4.8	23
54	Differences in antigenic sites and other functional regions between genotype A and G mumps virus surface proteins. <i>Scientific Reports</i> , 2018, 8, 13337.	3.3	22

#	ARTICLE	IF	CITATIONS
55	Safety and immunogenicity of an MF59 <sup>®</sup> -adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. <i>Vaccine</i> , 2015, 33, 174-181.	3.8	21
56	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. <i>Gut</i> , 2016, 65, 2029-2034.	12.1	21
57	Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials. <i>Vaccine Journal</i> , 2017, 24, .	3.1	21
58	Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. <i>Vaccine</i> , 2014, 32, 3694-3705.	3.8	20
59	Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium. <i>Scientific Reports</i> , 2019, 9, 20362.	3.3	20
60	Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice. <i>Malaria Journal</i> , 2013, 12, 430.	2.3	19
61	Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients. <i>Journal of Immunological Methods</i> , 2014, 414, 1-10.	1.4	19
62	Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 596-608.	3.3	19
63	Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. <i>World Journal of Gastroenterology</i> , 2014, 20, 15975.	3.3	19
64	Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked. <i>Journal of General Virology</i> , 2005, 86, 323-331.	2.9	18
65	Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 AS04-Adjuvanted Cervical Cancer Vaccine. <i>Vaccine Journal</i> , 2011, 18, 1510-1518.	3.1	18
66	Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1254-1262.	3.3	18
67	A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. <i>Antiviral Research</i> , 2017, 148, 53-64.	4.1	18
68	Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial. <i>Journal of Infectious Diseases</i> , 2019, 220, 1816-1825.	4.0	18
69	Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 2570-2579.	5.8	18
70	Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. , 2000, 60, 126-132.		17
71	Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG <sup>®</sup> KO Mice. <i>Methods in Molecular Biology</i> , 2017, 1506, 117-130.	0.9	17
72	Human Skin-Derived Precursor Cells Are Poorly Immunogenic and Modulate the Allogeneic Immune Response. <i>Stem Cells</i> , 2014, 32, 2215-2228.	3.2	16

#	ARTICLE	IF	CITATIONS
73	A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2022, 225, 1399-1410.	4.0	16
74	Metabolism of methylstenbolone studied with human liver microsomes and the uPA <sup>+</sup> /SCID chimeric mouse model. <i>Biomedical Chromatography</i> , 2014, 28, 974-985.	1.7	15
75	Characterization of HLA DR13-restricted CD4+ T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B. <i>Journal of General Virology</i> , 2002, 83, 3023-3033.	2.9	15
76	Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine. <i>Vaccine Journal</i> , 2014, 21, 302-311.	3.1	13
77	Development of prophylactic and therapeutic vaccines against hepatitis C virus. <i>Expert Review of Vaccines</i> , 2005, 4, 351-371.	4.4	12
78	Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e320-e329.	2.0	12
79	Immunogenicity and safety of cell-derived MF59 <sup>®</sup> -adjuvanted A/H1N1 influenza vaccine for children. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 358-376.	3.3	12
80	Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine. <i>Frontiers in Immunology</i> , 2022, 13, 852904.	4.8	12
81	A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2016, 15, 543.	2.3	10
82	Genetic and Antigenic Typing of Seasonal Influenza Virus Breakthrough Cases from a 2008-2009 Vaccine Efficacy Trial. <i>Vaccine Journal</i> , 2014, 21, 271-279.	3.1	9
83	A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. <i>Vaccine</i> , 2017, 35, 6700-6706.	3.8	8
84	A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 45-58.	3.3	8
85	Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. <i>Virology</i> , 2018, 514, 30-41.	2.4	8
86	Blocking HCV entry as potential antiviral therapy. <i>Future Virology</i> , 2012, 7, 547-561.	1.8	7
87	Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice. <i>Methods in Molecular Biology</i> , 2015, 1325, 59-68.	0.9	7
88	Clinical trials with GMO-containing vaccines in Europe: Status and regulatory framework. <i>Vaccine</i> , 2019, 37, 6144-6153.	3.8	7
89	Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group <sup>1</sup> . <i>Emerging Infectious Diseases</i> , 2020, 26, 2118-2128.	4.3	7
90	Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. <i>Vaccine</i> , 2020, 38, 3227-3234.	3.8	7

#	ARTICLE	IF	CITATIONS
91	Pregnancy has a minimal impact on the acute transcriptional signature to vaccination. <i>Npj Vaccines</i> , 2020, 5, 29.	6.0	7
92	<i>In vitro</i> and <i>in vivo</i> metabolism studies of dimethazine. <i>Biomedical Chromatography</i> , 2016, 30, 1202-1209.	1.7	6
93	Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6 <sup>+</sup> cell-line: a phase 1 randomized controlled trial in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1366-1373.	3.3	6
94	Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and <i>post-hoc</i> correlate of protection analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3043-3055.	3.3	5
95	Long-term immunogenicity and safety of a non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine: 4-year follow-up of a phase 1 multicentre trial. <i>Vaccine: X</i> , 2021, 9, 100124.	2.1	5
96	Head-to-head comparison of pandemic influenza vaccines. <i>Lancet Infectious Diseases</i> , 2011, 11, 74-75.	9.1	3
97	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. <i>Vaccine</i> , 2020, 38, 1678-1689.	3.8	2
98	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384.	2.5	2
99	Hepatitis B vaccines: accomplishments, shortcomings, and future developments. <i>The Southern African Journal of Epidemiology &amp; Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa</i> , 2008, 23, 33-37.	0.2	1
100	Metabolic studies of prostanazol with the uPA-SCID chimeric mouse model and human liver microsomes. <i>Steroids</i> , 2016, 107, 139-148.	1.8	1
101	1531. A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 Is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S475-S475.	0.9	1
102	Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. <i>Journal of Medical Virology</i> , 2000, 60, 126.	5.0	1
103	1110 Identification of Formulations and Vaccine Schedules of a Trivalent Group B Streptococcus Vaccine for Further Development in Non-pregnant and Pregnant Women. <i>Open Forum Infectious Diseases</i> , 2014, 1, S329-S329.	0.9	0
104	Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination with Heplisav <sup>®</sup> , compared with Engerix-B <sup>®</sup> vaccine in adults. <i>Vaccine</i> , 2015, 33, 3161.	3.8	0
105	Safety and Immunogenicity of Different Formulations of the Takeda Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
106	Adjuvanted herpes zoster subunit vaccine. <i>Future Virology</i> , 2016, 11, 5-18.	1.8	0
107	LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac <sup>®</sup> and Engerix B <sup>®</sup> (PROTECT). <i>Open Forum Infectious Diseases</i> , 2019, 6, S998-S998.	0.9	0
108	Late Breaking Abstract - Safety and immunogenicity of non-typeable <i>H. influenzae</i> (NTHi) and <i>M. catarrhalis</i> (Mcat) adjuvanted vaccines in adults. , 2018, , .		0